Private foundations providing support, resources, and advocacy for individuals and families affected by rare diseases have ...
Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...
The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...
"Living with kidney disease is a difficult challenge to navigate for patients and their families, and it can feel even more isolating and frustrating when you are living with a rare kidney disease,” ...
Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.
Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...
Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Vertex Pharmaceuticals EVP Edward Atkinson sold 1,767 shares for $849,838 on Feb. 25, 2025. This transaction, conducted under ...
Arc’teryx unveils its 2025 footwear lineup, featuring the Norvan LD 4, Vertex Speed, and Konseal, designed to enhance ...
Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...